Novo Nordisk is ramping up the manufacturing capacity of its obesity-related drugs as demand for Wegovy and Ozempic continues to surge. It's pouring $4.1 billion to expand its facility.

Novo Nordisk, the Danish drug maker of the wildly successful obesity drugs, Wegovy and Ozempic, said it plans to invest $4.1 billion for a new plant in the United States to increase the ...

Since launching Wegovy in the U.S. in mid-2021, Novo has spent billions to boost ... Nordisk. Niels Laurbjerg Nielsen, a corporate vice president at Novo who is in charge of fill-finish ...

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.

Analysis-Novo Nordisk Should Look to the US for Its ... CEO of Novo Nordisk Lars Fruergaard Jorgensen is seen during the 6th ... who campaigned on a promise to boost domestic manufacturing, ...

Novo Nordisk is ramping up the manufacturing capacity of its obesity-related drugs as demand for Wegovy and Ozempic continues to surge. It's pouring $4.1 billion to expand its facility.

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.

Novo Nordisk parent’s huge manufacturing deal is one step closer to closing. Meanwhile, Nobel Prize winners urge senators to oppose confirmation of RFK Jr.